MUFG Securities EMEA plc Takes Position in Bausch Health Cos Inc. $BHC

MUFG Securities EMEA plc bought a new stake in Bausch Health Cos Inc. (NYSE:BHC) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 3,400,000 shares of the company’s stock, valued at approximately $22,644,000. Bausch Health Cos makes up approximately 0.0% of MUFG Securities EMEA plc’s investment portfolio, making the stock its 19th largest holding. MUFG Securities EMEA plc owned about 0.92% of Bausch Health Cos as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in BHC. Nomura Holdings Inc. boosted its stake in shares of Bausch Health Cos by 106.2% in the 1st quarter. Nomura Holdings Inc. now owns 23,395,000 shares of the company’s stock valued at $151,366,000 after purchasing an additional 12,050,000 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Bausch Health Cos by 4,134.7% in the first quarter. Acadian Asset Management LLC now owns 673,316 shares of the company’s stock valued at $4,347,000 after buying an additional 657,416 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Bausch Health Cos by 97.1% in the first quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company’s stock valued at $6,136,000 after buying an additional 467,270 shares during the last quarter. Cubist Systematic Strategies LLC raised its holdings in shares of Bausch Health Cos by 162.9% in the first quarter. Cubist Systematic Strategies LLC now owns 607,656 shares of the company’s stock valued at $3,933,000 after buying an additional 376,518 shares during the last quarter. Finally, Nuveen LLC bought a new position in shares of Bausch Health Cos in the first quarter valued at about $1,473,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Wall Street Zen raised Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a report on Saturday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bausch Health Cos in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $9.00.

Insiders Place Their Bets

In other news, Director John Paulson acquired 34,721,118 shares of the company’s stock in a transaction on Thursday, August 14th. The stock was purchased at an average cost of $9.00 per share, with a total value of $312,490,062.00. Following the acquisition, the director owned 70,755,869 shares of the company’s stock, valued at $636,802,821. This trade represents a 96.35% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders bought 37,964,167 shares of company stock worth $333,757,793. Insiders own 19.97% of the company’s stock.

Bausch Health Cos Stock Performance

Shares of NYSE:BHC opened at $7.04 on Friday. The stock has a market capitalization of $2.61 billion, a P/E ratio of 27.06 and a beta of 0.43. Bausch Health Cos Inc. has a 1-year low of $4.25 and a 1-year high of $9.85. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 141.90. The business has a 50-day moving average price of $6.70 and a two-hundred day moving average price of $6.12.

Bausch Health Cos (NYSE:BHC) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.97 by ($0.07). The firm had revenue of $2.57 billion for the quarter, compared to the consensus estimate of $2.47 billion. Bausch Health Cos had a negative return on equity of 852.36% and a net margin of 0.99%. Equities analysts predict that Bausch Health Cos Inc. will post 4.41 earnings per share for the current year.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.